International Application No PCT/EP2004/009202

		PCT	/EP2004/009202	
A. CLASSII IPC 7	FICATION OF SUBJECT MATTER C12Q1/37			
According to	n International Patent Classification (IPC) or to both national classif	ication and IPC		
Minimum do IPC 7		ation symbols)		
Documentat	ASSIFICATION OF SUBJECT MATTER  CLOUD 18 continuational Palent Classification (PC) or to both national dissolitation and IPC  LIUS SEARCHED  mentation searched (classification system followed by classification symbols)  7 C12Q  mentation searched other than minimum documentation to the extent that such documents are included in the fields searched  ordic data base consided during the international search (name of data base and, where practical, search terms used)  —Internal, BIOSIS, EMBASE, WPI Data, PAJ, Sequence Search  COMMENTS CONSIDERED TO BE RELEVANT  ory** Challon of document, with indication, where appropriate, of the relevant passages  DATABASE BIOSIS [Online]  BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PAJ, US; March 2003 (2003-03), GLATT C M ET AL: "Differentiation between  sensitizers and irritants in the local lymph node assay using a minimal transcript set."  XP002312204  Database accession no. PREV200300221396  abstract  & TOXICOLOGICAL SCIENCES, vol. 72, no. S-1, March 2003 (2003-03), page 264, 42RD ANNUAL MEETING OF THE SOCIETY OF TOXICOLOGY SALT LAKE CITY, UTAH, USA; MARCH 99-13, 2003  ISSN: 1096-6080  —//-  Further documents are listed in the continuation of box C.  Calc attagenties of citied documents:  comment defining this general states of the continuation of box C.  Calc attagenties of citied documents:  comment defining the parental states of the continuation of box C.  Calc attagenties of citied documents:  comment defining the parental states of the continuation of box C.  Calc attagenties of citied documents:  comment defining the parental states of the continuation of box C.  Calc attagenties of citied documents:  comment defining the parental states of the continuation of box C.  Calc attagenties of citied documents:  comment engage and a continuation of the continuation of box C.  Calc attagenties of citied documents:  comment engage and a continuation of the			
		•	•	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.	
A	BIOSCIENCES INFORMATION SERVICE PHILADELPHIA, PA, US; March 2003 (2003-03), GLATT C M ET AL: "Differentiati sensitizers and irritants in the lymph node assay using a minimal transcript set." XP002312204 Database accession no. PREV2003 abstract & TOXICOLOGICAL SCIENCES, vol. 72, no. S-1, March 2003 (2 page 264, 42ND ANNUAL MEETING OF THE SOCI TOXICOLOGY; SALT LAKE CITY, UTAMARCH 09-13, 2003	on between le local l	1-25	
X Furt	ther documents are listed in the continuation of box C.	X Patent family member	s are listed in annex.	
citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed		or priority date and not in cited to understand the prinvention  "X" document of particular relectant be considered no involve an inventive step  "Y" document of particular relectant be considered to indecument is combined with ments, such combination in the art.  "&" document member of the s	or priority date and not in conflict with the application but clied to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family	
•		1		
Name and	European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer		
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Gunster, M		

1

International Application No
PCT/EP2004/009202

		PC1/EP2004/009202		
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
А	YOUSEF G M ET AL: "The Expanded Human Kallikrein Gene Family: Locus Characterization and Molecular Cloning of a New Member, KLK-L3 (KLK9)" GENOMICS, vol. 65, no. 2, 15 April 2000 (2000-04-15), pages 184-194, XP004439384 figure 6	1-25		
Α	YOUSEF GEORGE M ET AL: "The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer." BREAST CANCER RESEARCH AND TREATMENT, vol. 78, no. 2, March 2003 (2003-03), pages 149-158, XP002312203 the whole document	1-25		
A	WO 00/53776 A (MOUNT SINAI HOSPITAL CORP.) 14 September 2000 (2000-09-14) example 4	1-25		
A	WO 03/033731 A (MOUNT SINAI HOSPITAL CORP) 24 April 2003 (2003-04-24) claim 1	1-25		

1

International application No. PCT/EP2004/009202

ox II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)					
his International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. X Claims Nos.: 26 because they relate to subject matter not required to be searched by this Authority, namely:  Rule 39.1(iv) PCT - Method for treatment of the human or animal body by					
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy					
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:					
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)					
This International Searching Authority found multiple inventions in this international application, as follows:					
see additional sheet					
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.					
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not Invite payment of any additional fee.					
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:					
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:  1-25 (all partially)					
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.					

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-25[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with KLK9, in which the diseases are hematological diseases.

2. claims: 1-25[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with KLK9, in which the diseases are cardiovascular diseases.

claims: 1-25[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with KLK9, in which the diseases are neurological disorders.

4. claims: 1-25[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with KLK9, in which the diseases are metabolic disorders.

5. claims: 1-25[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with KLK9, in which the diseases are urological diseases.

6. claims: 1-25[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with KLK9, in which the diseases are cancers.

7. claims: 1-25[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with KLK9, in which the diseases are inflammation diseases.

8. claims: 1-25[partially]

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with KLK9, in which the diseases are dermatological disorders.

9. claims: 1-25[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with KLK9, in which the diseases are gastroenterological diseases.

Information on patent family members

International Application No
PCT/EP2004/009202

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0053776	Α	14-09-2000	AU WO WO CA CA EP JP	3139800 A 3139900 A 0053776 A2 0053747 A1 2362885 A1 2366087 A1 1159431 A2 2002538789 T	28-09-2000 28-09-2000 14-09-2000 14-09-2000 14-09-2000 14-09-2000 05-12-2001 19-11-2002
WO 03033731	A	24-04-2003	WO CA EP	03033731 A2 2463920 A1 1436421 A2	24-04-2003 24-04-2003 14-07-2004